References
- Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJRM, Schönberger JPAM, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001; 344: 1117–24
- Serruys PW, Ong ATL, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJRM, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease. J Am Coll Cardiol. 2005; 46: 575–81
- Hoffman SN, TenBrook JA, Wolf MP, Pauker SG, Salem DN, Wong JB. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: One-to eight-year outcomes. J Am Coll Cardiol. 2003; 41: 1293–304
- Mark DB, Nelson CL, Califf RM, Harrell FE, Jr, Lee KL, Jones RH, et al. Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Circulation. 1994; 89: 2015–25
- Hannan EL, Racz MJ, McCallister BD, Ryan TJ, Arani DT, Isom OW, et al. A comparison of three-year survival after coronary artery bypass graft surgery and percutaneous transluminal coronaty angioplasty. J Am Coll Cardiol. 1999; 33: 63–72
- Smith PK, Califf RM, Tuttle RH, Shaw LK, Lee KL, Delong ER, et al. Selection of surgical or percutaneous coronary intervention provides differential longevity benefit. Ann Thorac Surg. 2006; 82: 1420–9
- Hannan EL, Racz MJ, Walford G, Jones RH, Ryan TJ, Bennett E, et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med. 2005; 352: 2174–83
- Mølstad P. Survival after percutaneous coronary intervention and coronary artery bypass grafting in a single centre. Scand Cardiovasc J. 2007 (in press).
- Babapulle MN, Joseph L, Bélisle P, Brophy JM, Eisenberg MJ, et al. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet. 2004; 364: 583–91
- Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995; 92: 657–71
- Klein LW. Are drug-eluting stents the preferred treatment for multivessel coronary artery disease?. J Am Coll Cardiol. 2006; 47: 22–6
- Farb A, Boam AB. Stent thrombosis redux – the FDA perspective. N Engl J Med. 2007; 356: 984–7
- Maisel WH. Unanswered questions – drug-eluting stents and the risk of late thrombosis. N Engl J Med. 2007; 356: 981–4